View Older Stories View More Recent Stories

Jan 5, 2016 01:07AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 22, 2015 01:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 17, 2015 01:05AM ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS
Dec 16, 2015 12:13PM ABLYNX ANNOUNCES WARRANT EXERCISE
Dec 11, 2015 01:00AM Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
Dec 11, 2015 01:00AM Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access
Dec 9, 2015 01:07AM ABLYNX ANNOUNCES WARRANT EXERCISE
Dec 2, 2015 01:04AM JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX
Dec 1, 2015 01:05AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Nov 30, 2015 01:14AM ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER
Nov 25, 2015 01:06AM ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK
Nov 24, 2015 01:00AM Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled
Nov 19, 2015 07:00AM Canadian Solar Subsidiary Recurrent Energy Closes Financing for 100 Megawatt Astoria Solar Power Project
Nov 18, 2015 01:08AM ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015
Nov 10, 2015 06:01PM Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Nov 10, 2015 06:00PM Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Nov 8, 2015 07:08AM Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Nov 8, 2015 07:00AM Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Nov 5, 2015 08:00AM Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015
Nov 5, 2015 01:05AM ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY
Oct 27, 2015 09:00AM Integrated PR and Digital Marketing Continues to Fuel Growth at PAN Communications
Oct 21, 2015 01:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Oct 20, 2015 08:25AM BNY Mellon Selected as Depositary Bank by Banco Santander Brasil S.A.
Oct 15, 2015 01:09AM ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
Oct 6, 2015 02:55PM Santander evacuates Madrid office after likely 'white powder' hoax
Oct 5, 2015 09:00AM Genzyme Introduces “vs.MS,” a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed Care
Sep 29, 2015 01:04AM ABLYNX INITIATES A MULTINATIONAL PHASE III STUDY WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP, A RARE BLOOD CLOTTING DISORDER
Sep 28, 2015 01:00AM Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Sep 9, 2015 07:00AM Cloudera Launches Effort to Unite Apache Spark and Apache Hadoop
Sep 8, 2015 07:00AM Canadian Solar Subsidiary Recurrent Energy Secures Financing for 100 Megawatt Mustang Solar Power Project
Sep 1, 2015 09:00AM Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
Aug 27, 2015 01:06AM ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015
Aug 20, 2015 08:35AM Keynote Speakers Announced for NORD's Rare Diseases & Orphan Products Breakthrough Summit
Aug 20, 2015 08:30AM Every Dog Has A Funny Bone: Share Your Doggone Funny Stories With Merial, The Maker Of NexGard® (afoxolaner), For An Opportunity To Win $5,000
Aug 19, 2015 01:04AM ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST
Aug 14, 2015 01:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Aug 5, 2015 10:04AM BNY Mellon Appointed as Successor Depositary Bank by Banco Santander Chile
Aug 4, 2015 01:06AM ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Jul 31, 2015 01:05AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 29, 2015 01:05AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jul 22, 2015 01:08AM ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
Jul 20, 2015 01:04AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 14, 2015 01:11AM OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX
Jul 1, 2015 01:07AM TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 5.14% SHAREHOLDING IN ABLYNX
Jun 16, 2015 12:49PM Santander Donates $175,000 To The American Red Cross
May 13, 2015 07:00AM Calling All Dog Owners: Profess Your Love For Your Precious Pup With The "I HEART My Dog" Program From Merial, The Maker Of HEARTGARD® Plus (ivermectin/pyrantel), To Support Canine Companio
May 8, 2015 07:30AM Neuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update
May 6, 2015 07:31AM Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer
Apr 30, 2015 07:53AM Sanofi Delivers Q1 2015 Business EPS Growth of 2.6% at CER and 12.8% on a Reported Basis
Apr 22, 2015 01:09PM Santander And New England Revolution Launch 2015 Santander Soccer Scholars Program
View More Recent Stories View Older Stories